France· FR:61365985
SAPHNELO 300 mg, solution à diluer pour perfusion
A medicinal product containing anifrolumab, registered in France by ASTRAZENECA AB.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ANIFROLUMAB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550873661 flacon(s) en verre de 2 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsSaphnelo 300 mg, concentraat voor oplossing voor infusieAstraZeneca AB
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- SwitzerlandSaphnelo 120 mg/0.8 ml, Injektionslösung in einem FertigpenAstraZeneca AG
- BelgiumSaphnelo 120 mgAstraZeneca
- IrelandSaphnelo 120 mg solution for injection in pre-filled penAstraZeneca AB
- IcelandSaphneloAstraZeneca AB*
- PolandSaphneloAstraZeneca AB
- SwedenSaphnelo 120 mg Injektionsvätska, lösning i förfylld injektionspennaAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Saphnelo
- Liechtenstein · Saphnelo
- Norway · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5fdb496d-fba5-4e7e-ae9c-2d9135bb00bd GET /v1/drugs/5fdb496d-fba5-4e7e-ae9c-2d9135bb00bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61365985",
"date_amm": "2022-02-14",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1623",
"substance": "ANIFROLUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.